HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

eprosartan (Teveten)

angiotensin II receptor antagonist; structure given in first source

Also Known As:

Teveten; (4-carboxybenzyl)imidazole-5-acrylic acid; SK&F 108566; SKF-108566; 2-Thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lH-imidazol-5-yl)methylene)-, (E)-

Networked: 122 relevant articles (17 outcomes, 48 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Experts

1.	de la Sierra, Alejandro: 5 articles (06/2009 - 10/2004)
2.	Ram, C Venkata S: 3 articles (11/2007 - 11/2007)
3.	Schrader, Joachim: 2 articles (09/2009 - 06/2005)
4.	Lüders, Stephan: 2 articles (09/2009 - 06/2005)
5.	Hill, Michael D: 2 articles (05/2009 - 02/2006)
6.	Sachse, A: 2 articles (09/2008 - 03/2002)
7.	Robles, N R: 2 articles (01/2008 - 04/2005)
8.	Martín-Agueda, B: 2 articles (01/2008 - 04/2005)
9.	López-Muñoz, F: 2 articles (01/2008 - 04/2005)
10.	Alamo, C: 2 articles (01/2008 - 04/2005)

Related Diseases

1.	Hypertension (High Blood Pressure) 09/01/1999 - "In the recommended dose range of 600 to 1200 mg once daily, eprosartan is effective in patients with all grades of hypertension irrespective of age, sex, or race. " 06/01/1999 - "When taken in the recommended dose range, 600-800 mg once daily, eprosartan is effective in patients with all grades of hypertension, regardless of age, sex or race. " 01/01/2002 - "Monotherapy with eprosartan mesilat was effective in all patients with moderate arterial hypertension and in 43.6% in patients with severe arterial hypertension. " 01/01/2001 - "Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension." 01/01/2009 - "Eprosartan also reduced blood pressure and was associated with a modest improvement in cognitive function in a large observational study in patients > or =50 years of age with newly diagnosed hypertension (OSCAR study). " Order ALL the reference details at left...
2.	Stroke (Strokes) 01/01/2002 - "Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. " 11/01/2007 - "Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline." 03/01/2007 - "Eprosartan in secondary prevention of stroke: the economic evidence." 06/01/2001 - "CONCLUSION: These data demonstrate that eprosartan, at a clinically relevant dose, provides significant end-organ protection in the severely hypertensive stroke-prone rat. " 01/01/2003 - "Twenty patients with stroke of hemisphere localization developed as a result of arterial hypertension were treated with eprosartan mesilat. " Order ALL the reference details at left...
3.	Disease Progression 09/01/1999 - "In various animal models of disease, including hypertension and stroke, eprosartan is effective in reducing disease progression. " 06/01/1999 - "Eprosartan is effective in reducing disease progression in animal models of hypertension, heart failure, renal disease and stroke. " Order ALL the reference details at left...
4.	Heart Failure 06/01/2005 - "[Effect of a combination of teveten and prestarium in patients with chronic heart failure]" 01/01/2003 - "1. We examined the effects of eprosartan, an AT(1) receptor antagonist, on the progression of left ventricular (LV) dysfunction and remodelling in dogs with heart failure (HF) produced by intracoronary microembolizations (LV ejection fraction, EF 30 to 40%). " 10/01/1998 - "Moreover, eprosartan caused a preferential increase in renal cortical blood perfusion and significantly increased glomerular filtration in rats with congestive heart failure. " 01/01/2003 - "Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure." 10/01/1998 - "Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure." Order ALL the reference details at left...
5.	Cough 01/01/2009 - "Eprosartan was generally well tolerated in clinical trials and had a lower incidence of persistent dry cough than enalapril. " 11/01/2007 - "In clinical studies, eprosartan has been shown to significantly reduce cardiovascular and cerebrovascular events, whilst avoiding the persistent cough that commonly occurs with the use of angiotensin-converting enzyme inhibitors. " 12/01/2001 - "At study end point 23% of patients in the enalapril group and 5% in the eprosartan and placebo groups reported cough (which included definite, probable and possible coughs) (P = 0.02). " 12/01/2001 - "Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo." 12/01/2001 - "Those on enalapril were twice as likely to have gained a definite or possible cough by study end point as those on eprosartan (7.6% vs 3.2%) P = 0.099. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Enalapril
2.	Angiotensin Receptors (Angiotensin II Receptor)
3.	Hydrochlorothiazide (Esidrix)
4.	eprosartan (Teveten)
5.	Nitrendipine
6.	Angiotensin II
7.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
8.	1H-tetrazole (tetrazole)
9.	diphenyl (biphenyl)
10.	Losartan (Cozaar)

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Light Coagulation
3.	Lasers (Laser)
4.	Renal Dialysis (Hemodialysis)

blog comments powered by Disqus

TREATMENT OPTIONS
for Hypertension,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 3904 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>